Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
David Kaminetzky1, Kenneth B Hymes21Division of Hematology/Oncology, New York University School of Medicine, New York, USA; 2New York University Cancer Institute, New York, USAAbstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as...
Guardado en:
Autores principales: | David Kaminetzky, Kenneth B Hymes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f82a9298b1741aeb1c6a723b6e91f15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Beate Hauptrock, et al.
Publicado: (2008) -
Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat
por: Zhang CL, et al.
Publicado: (2012) -
Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma
por: Christine L. Jones, et al.
Publicado: (2021) -
Cross-talk between Myc and p53 in B-cell lymphomas
por: Li Yu, et al.
Publicado: (2019) -
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
por: Fani Karagianni, et al.
Publicado: (2021)